Janux commences participant dosing in Phase I JANX011 trial

​Janux Therapeutics has dosed the first participant in a Phase I clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform.

The post Janux commences participant dosing in Phase I JANX011 trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Viome PRO introduces blood test for pancreatic cancer
Alpheus begins multi-centre study for butterfly GBM
Biohaven partners with Ono in $100m IgG degrader deal
The pitfalls in hospitals’ ability to auction clinical labour
BD reports nine-month AGILITY trial data for Revello stent

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us